ICRF 159, (+/-) 1,2-di(3,5-dioxopiperazin-1-yl) propane NSC-129,943; razoxane.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006224:Cricetinae; D004285:Dogs; D004357:Drug Synergism; D000882:Haplorhini; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D007938:Leukemia / Q000188:drug therapy; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy; D010879:Piperazines / Q000627:therapeutic use*; D011817:Rabbits; D011838:Radiation-Sensitizing Agents / Q000494:pharmacology; D051381:Rats; D011929:Razoxane / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D013723:Teratogens / Q000494:pharmacology
D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D010879:Piperazines; D011838:Radiation-Sensitizing Agents; D013723:Teratogens; D011929:Razoxane